Jeffrey J. Brown has demonstrated a consistent buying bias across his reported insider transactions, with no recorded sales over 25 trades spanning two companies: Upbound Group (UPBD) and Medifast (MED). His total buy activity amounts to $1,666,261, concentrated primarily in UPBD, where he executed multiple acquisitions through open market purchases (Code A) and derivative transactions (Code P). Notably, Brown’s UPBD purchases follow a recurring pattern, with significant quarterly acquisitions—often exceeding $200,000—on or near the first trading day of January, April, July, and October. For example, on January 2, 2025, he acquired $242,636 worth of UPBD shares, mirroring similar-sized purchases on the same date in 2024 and 2026. His MED activity is less frequent but substantial, with two $126,000+ open-market purchases in June 2024 and 2025.
Recent filings show Brown’s UPBD acquisitions continuing into 2026, including a $40,060 open-market buy and $35,484 in derivative transactions on January 6. The absence of any sell transactions suggests a long-term accumulation strategy, particularly in UPBD, where derivative activity often accompanies direct purchases. While the derivative transactions—typically involving options—are smaller in scale (ranging from $8,469 to $35,484), they reinforce his bullish stance. The structured timing of major purchases, coupled with zero sales across both holdings, indicates a deliberate and sustained investment approach in these companies.
AI-assisted summary